Browse Our Resources
Video
DPA's video series, Matters of Substance, breaks down important drug policy concepts in under 60 seconds. Watch and learn in just a minute.
Got a suggestion for a future video? Email us at [email protected] and… Read More
Fact Sheet
The U.S. Food and Drug Administration (FDA) has approved three medications for use in treating opioid dependence: methadone, buprenorphine, and naltrexone. Extended release naltrexone, brand name Vivitrol®, is a… Read More
Fact Sheet
Under HAT, pharmacological heroin is administered under strict controls in a clinical setting to those who have struggled in other treatments like methadone. Every published evaluation of HAT has shown extremely… Read More
Statement of Support
On April 7, 2015, Ethan Nadelmann, Executive Director of the Drug Policy Alliance, presented oral testimony in support of sections 11-20 of SB275 at a hearing of the Nevada State Senate Revenue and Economic Development… Read More
Fact Sheet
The U.S. refuses to adopt an evidence-based HIV/AIDS prevention strategy, costing us hundreds of thousands of lives and hundreds of millions of dollars. However, in countries where addiction is treated as a health issue… Read More
Report
The ideal resource for anyone interested in learning about methadone maintenance therapy and buprenorphine therapy, this booklet was designed for treatment providers, people in recovery, and their families.